California, 18 States Sue to Block Trump’s $100,000 H-1B Visa Fee 
Russian Drone Attack Hits Turkish Cargo Ship Carrying Sunflower Oil to Egypt, Ukraine Says 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Israeli Airstrike in Gaza Targets Senior Hamas Commander Amid Ceasefire Tensions 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Judge Orders Return of Seized Evidence in Comey-Related Case, DOJ May Seek New Warrant 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Belarus Frees Opposition Leaders Maria Kalesnikava and Viktar Babaryka in U.S.-Brokered Deal 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Syria Arrests Five Suspects After Deadly Attack on U.S. and Syrian Troops in Palmyra 
Cantor Fitzgerald analysts are calling for the dismissal of U.S. Health and Human Services Secretary Robert F. Kennedy Jr., citing his controversial anti-vaccine views and lack of scientific expertise. In a note released Monday, Cantor’s Josh Schimmer and Eric Schmidt warned that Kennedy is “undermining the trusted leadership of health care in this country.”
Kennedy recently announced plans to restructure federal health agencies, potentially firing thousands of staff. The move comes on the heels of the resignation of Peter Marks, the FDA’s top vaccine official, who reportedly left under pressure from the administration. Marks had been known for his data-driven approach to vaccine safety and his resistance to what Cantor described as an “anti-science agenda.”
Biotech and vaccine stocks dropped following Marks’ resignation, with the SPDR S&P Biotech ETF (NYSE:XBI) falling 3.9%. Despite the market reaction, Cantor analysts stressed their concerns were about public health, not politics or stock performance.
Cantor Fitzgerald, a major Wall Street firm previously led by Howard Lutnick—now Commerce Secretary under Trump—has recently passed leadership to his sons. Brandon Lutnick now serves as chairman, while Kyle Lutnick holds the position of executive vice chairman.
The analysts expressed hope that Washington leadership will recognize the critical role of vaccines in safeguarding public health. They emphasized the need for scientifically grounded leadership at the Department of Health and Human Services, warning that Kennedy’s conspiracy-driven stance could endanger lives.
Cantor Fitzgerald has yet to comment publicly on the matter.
This development marks a significant flashpoint in the Trump administration’s overhaul of federal health agencies, stirring concern among biotech investors and public health experts alike.
